Literature DB >> 22460584

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.

Omar Abdel-Wahab1, Animesh Pardanani, Olivier A Bernard, Guido Finazzi, John D Crispino, Heinz Gisslinger, Robert Kralovics, Olatoyosi Odenike, Kapil Bhalla, Vikas Gupta, Giovanni Barosi, Jason Gotlib, Paola Guglielmelli, Jean-Jacques Kiladjian, Pierre Noel, Mario Cazzola, Alessandro M Vannucchi, Ronald Hoffman, Tiziano Barbui, Juergen Thiele, Richard A Van Etten, Tariq Mughal, Ayalew Tefferi.   

Abstract

Immediately after the annual scientific meeting of the American Society of Hematology (ASH), a select group of clinical and laboratory investigators in myeloproliferative neoplasms (MPN) is summoned to a post-ASH conference on chronic myeloid leukemia and the BCR-ABL1-negative MPN. The 6th such meeting occurred on December 13–14,2011, in La Jolla, California, USA, under the direction of its founder,Dr. Tariq Mughal. The current document is the first of two reports on this post-ASH event and summarizes the most recent preclinical and clinical advances in polycythemia vera, essential thrombocythemia,and primary myelofibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460584      PMCID: PMC3491640          DOI: 10.1002/ajh.23169

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  47 in total

1.  Long-term outcome of pomalidomide therapy in myelofibrosis.

Authors:  Kebede H Begna; Animesh Pardanani; Ruben Mesa; Mark R Litzow; William J Hogan; Curtis A Hanson; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-11-12       Impact factor: 10.047

2.  Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.

Authors:  Yu-Fei He; Bin-Zhong Li; Zheng Li; Peng Liu; Yang Wang; Qingyu Tang; Jianping Ding; Yingying Jia; Zhangcheng Chen; Lin Li; Yan Sun; Xiuxue Li; Qing Dai; Chun-Xiao Song; Kangling Zhang; Chuan He; Guo-Liang Xu
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

3.  EZH2 mutational status predicts poor survival in myelofibrosis.

Authors:  Paola Guglielmelli; Flavia Biamonte; Joannah Score; Claire Hidalgo-Curtis; Francisco Cervantes; Margherita Maffioli; Tiziana Fanelli; Thomas Ernst; Nils Winkelman; Amy V Jones; Katerina Zoi; Andreas Reiter; Andrew Duncombe; Laura Villani; Alberto Bosi; Giovanni Barosi; Nicholas C P Cross; Alessandro M Vannucchi
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

4.  Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors:  Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.

Authors:  J B Demoulin; C Uyttenhove; D Lejeune; A Mui; B Groner; J C Renauld
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

7.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

8.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1.

Authors:  Victoria Valinluck; Lawrence C Sowers
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

View more
  12 in total

Review 1.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 2.  Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Authors:  B L Stein; R Swords; A Hochhaus; F Giles
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

Review 3.  Signal transduction in the chronic leukemias: implications for targeted therapies.

Authors:  Wesam Ahmed; Richard A Van Etten
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

4.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

Review 5.  Practical management of patients with myelofibrosis receiving ruxolitinib.

Authors:  Claire Harrison; Ruben Mesa; David Ross; Adam Mead; Clodagh Keohane; Jason Gotlib; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

Review 6.  Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Authors:  J Mascarenhas; T I Mughal; S Verstovsek
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.

Authors:  Jason D Merker; Krishna M Roskin; Dana Ng; Cuiping Pan; Dianna G Fisk; Jasmine J King; Ramona Hoh; Michael Stadler; Lawrence M Okumoto; Parveen Abidi; Rhonda Hewitt; Carol D Jones; Linda Gojenola; Michael J Clark; Bing Zhang; Athena M Cherry; Tracy I George; Michael Snyder; Scott D Boyd; James L Zehnder; Andrew Z Fire; Jason Gotlib
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 11.047

8.  Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Authors:  Qiang Jeremy Wen; Qiong Yang; Benjamin Goldenson; Sébastien Malinge; Terra Lasho; Rebekka K Schneider; Lawrence J Breyfogle; Rachael Schultz; Laure Gilles; Priya Koppikar; Omar Abdel-Wahab; Animesh Pardanani; Brady Stein; Sandeep Gurbuxani; Ann Mullally; Ross L Levine; Ayalew Tefferi; John D Crispino
Journal:  Nat Med       Date:  2015-11-16       Impact factor: 53.440

Review 9.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14

Review 10.  Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.

Authors:  Ruben A Mesa; Jorge Cortes
Journal:  J Hematol Oncol       Date:  2013-10-22       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.